Skip to main
  1. Stocks
  2. Cardinal Health
  3. Forecast
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 54%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is positioned for durable fundamental outperformance because F1Q27 results and raised FY27 guidance reinforce broad-based profit growth across Pharma and Other, with adjusted EPS now expected at $12.80-$13.00 and Pharma profit growth at 10%-12%. Its core distribution scale, strength in specialty and generics, and vertical integration into higher-margin services such as Sonexus and nuclear medicine should expand operating income, while the Other segment’s revenue and profit growth of 12%-14% and 17%-20% adds a meaningful growth engine. Even with slower Pharma growth in F2Q/F3Q from renewal timing, continued customer wins, biosimilar adoption, and specialty-drug momentum support a stronger FY27 and a widening moat versus peers.

Bears say

Cardinal Health is facing a fundamental risk profile that is unfavorable because its core drug distribution business operates in a highly competitive market with razor-thin low-single-digit gross margins, while supply chain disruptions and input cost inflation could further compress profitability. Its growth case is also fragile: the tailwinds from generics are expected to taper off, specialty growth may prove less durable, and execution risk around the GMPD improvement plan, Sonexus expansion, and capital deployment could limit margin expansion. At the same time, the stock trades at 18x NTM+1 PE, over 2-standard deviations above its 5-year average, leaving limited valuation support if nuclear FDA approvals, radioisotope supply, or healthcare policy changes disappoint.

Cardinal Health (CAH) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 54% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Cardinal Health (CAH) Analyst Forecast & Price Prediction

Get the latest Cardinal Health (CAH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cardinal Health (CAH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 13 analysts, Cardinal Health (CAH) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $294.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $294.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Cardinal Health (CAH) Analyst Forecast & Price Prediction

Get the latest Cardinal Health (CAH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cardinal Health (CAH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CAH stock data and trends